Search
for

    Glossary Skindex-16

    dermatology questionnaire assessing skin condition impact on quality of life

    Skindex-16 is a dermatology-specific questionnaire designed to measure the impact of skin conditions on a patient's quality of life. It consists of 16 questions that assess symptoms, emotions, and functioning, providing valuable insights for both patients and healthcare professionals to evaluate the psychological and social effects of skin diseases like alopecia.

    Related Terms

    Research 10 of 229

    1. Arabic version of Skindex‐16: Translation and cultural adaptation, with assessment of reliability and validity International Journal of Dermatology · 2007 · 24 citations
    2. Validation of an Egyptian Arabic Version of Skindex-16 and Quality of Life Measurement in Egyptian Patients with Skin Disease International Journal of Behavioral Medicine · 2017 · 17 citations
    3. PCR30 PSYCHOMETRIC EVALUATION OF SKINDEX-16 AA, THE ALOPECIA AREATA SYMPTOM IMPACT SCALE (AASIS), AND THE SCALP HAIR ASSESSMENT PATIENT-REPORTED OUTCOME (PRO) IN ADULTS AND ADOLESCENTS WITH SEVERE ALOPECIA AREATA Value in Health · 2026
    4. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia Journal of The American Academy of Dermatology · 2011 · 86 citations
    5. Clinician vs Self-ratings of Hirsutism in Patients With Polycystic Ovarian Syndrome JAMA dermatology · 2016 · 52 citations
    6. Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials SKIN The Journal of Cutaneous Medicine · 2023 · 4 citations
    7. Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) · 2026
    8. 63532 Impact of Eyebrow and Eyelash Hair Loss on Health-Related Quality of Life Among Patients with Alopecia Areata: Results From a Real-World Survey in 5 European Countries Journal of the American Academy of Dermatology · 2025
    9. 0475 High-dose UVA-1 therapy improves patient-reported outcomes and clinical scores in patients with sclerosing skin disease Journal of Investigative Dermatology · 2025
    10. Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials JEADV Clinical Practice · 2023
    All research results →

    Learn

    — no results

    Try a deeper search in learn →

    Community

    — no results

    Try a deeper search in community →